Skip to main content

Advertisement

SpringerLink
Log in

Prediction of Successful Outcome in Patients with Primary Aldosteronism

  • Endocrine Tumors
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Primary aldosteronism is one of the most common causes of secondary hypertension. In recent years the prevalence has risen dramatically, from 1% to 14% of all hypertensive patients. This has been largely attributed to an increase in diagnosis. Primary aldosteronism is characterized by hypertension with or without hypokalemia and a high plasma aldosterone concentration (PAC) with a concurrent low plasma renin activity (PRA). The most common subtypes of primary aldosteronism are aldosterone-producing adenoma (42%) and bilateral idiopathic hyperaldosteronism (58%). Other less common subtypes (<1%) are glucocorticoid-remediable aldosteronism, and unilateral primary hyperplasia. Current treatment for primary aldosteronism relies on accurate subtype distinction and assessment of unilateral versus bilateral disease. Bilateral idiopathic hyperaldosteronism is best managed pharmacologically and improves with the use of aldosterone receptor antagonists. Combined treatment with sodium-channel blockers and calcium-channel blockers has also shown satisfactory results. Glucocorticoid-remediable aldosteronism responds well to treatment with low-dose glucocorticoids. Aldosterone producing adenoma and unilateral adrenal hyperplasia are appropriately treated with laparoscopic adrenalectomy. Following adrenalectomy blood pressure improves in 98% of these patients, but only about 33% require no further antihypertensive medication. Identifying the subgroups that will most benefit from adrenalectomy is paramount to formulating individual treatment strategies. In the past, treatment focused mainly on the correction of hypertension and electrolyte disturbances. Now, with accumulating evidence of the detrimental effects of aldosterone to the myocardium, vascular endothelium and kidneys, treatment also focuses on normalizing aldosterone levels or blocking aldosterone action at the receptor level. Therefore, it is essential to accurately identify the specific subtype of primary aldosteronism in order to select optimal treatment and to achieve successful patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Plouin PF, Amar L, Chatellier G: Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 2004, 19:774–777

    Article  PubMed  Google Scholar 

  2. Rossi GP, Bernini G, Caliumi C, et al.: A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293–2300

    Article  PubMed  CAS  Google Scholar 

This is one of the largest prospective studies looking at the prevalence of primary aldosteronism in newly diagnosed hypertensive patients.

  1. Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243–1248

    Article  PubMed  CAS  Google Scholar 

  2. Giacchetti G, Ronconi V, Turchi F, et al.: Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007, 25:177–186

    Article  PubMed  CAS  Google Scholar 

  3. Mantero F, Mattarello MJ, Albiger NM: Detecting and treating primary aldosteronism: primary aldosteronism. Exp Clin Endocrinol Diabetes 2007, 115:171–174

    Article  PubMed  CAS  Google Scholar 

Offers an in-depth look at the diagnosis of primary aldosteronism.

  1. Agharazii M, Douville P, Grose JH, et al.: Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension, 2001 37:1440–1443

    PubMed  CAS  Google Scholar 

  2. Rossi GP, Sacchetto A, Chiesura-Corona M et al.: Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001, 86:1083–1090

    Article  PubMed  CAS  Google Scholar 

  3. Young WF, Stanson AW, Thompson GB, et al.: Role for adrenal venous sampling in primary aldosteronism. Surgery 2004, 136:1227–1235

    Article  PubMed  Google Scholar 

  4. Tan YY, Ogilvie JB, Triponez F, et al.: Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World J Surg 2006, 30:879–885; discussion 886–877

    Google Scholar 

  5. Hallfeldt KK, Mussack T, Trupka A, et al. Laparoscopic lateral adrenalectomy versus open posterior adrenalectomy for the treatment of benign adrenal tumors. Surg Endosc 2003, 17:264–267

    Article  PubMed  CAS  Google Scholar 

  6. Sawka AM, Young WF, Thompson GB, et al.: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258–261

    PubMed  CAS  Google Scholar 

  7. Gockel I, Heintz A, Polta M, et al.: Long-term results of endoscopic adrenalectomy for Conn’s syndrome. Am Surg 2007, 73:174–180

    PubMed  Google Scholar 

  8. Meyer A, Brabant G, Behrend M: Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 2005, 29:155–159

    Article  PubMed  Google Scholar 

  9. Young WF, Jr: Minireview: primary aldosteronism—changing concepts in diagnosis and treatment. Endocrinology 2003, 44:2208–2213

    Article  PubMed  CAS  Google Scholar 

An excellent review of primary aldosteronism.

  1. Janmohamed S, Bouloux PM: The pharmacological treatment of primary aldosteronism. Expert Opin Pharmacother 2006, 7:563–573

    Article  PubMed  CAS  Google Scholar 

A thorough overview of current medical therapy for primary aldosteronism.

  1. Mattsson C, Young WF, Jr: Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006, 2:198–208

    Article  PubMed  CAS  Google Scholar 

  2. Lim PO, Young WF, MacDonald TM: A review of the medical treatment of primary aldosteronism. J Hypertens 2001, 19:353–361

    Article  PubMed  CAS  Google Scholar 

  3. Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756–760

    Article  PubMed  CAS  Google Scholar 

  4. Zillich AJ, Carter BL: Eplerenone—a novel selective aldosterone blocker. Ann Pharmacother 2002, 36:1567–1576

    Article  PubMed  CAS  Google Scholar 

  5. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709–716

    Article  PubMed  CAS  Google Scholar 

  6. Bravo EL: Medical management of primary hyperaldosteronism. Curr Hypertens Rep 2001, 3:406–409

    Article  PubMed  CAS  Google Scholar 

  7. Bubbar CD, Blackburn DF, Wilson MP, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion. Ann Pharmacother 2007, 41:129–132

    PubMed  CAS  Google Scholar 

  8. Stokes GS, Monaghan JC, Ryan M, et al.: Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism. J Hypertens 2001, 19:1161–1165

    Article  PubMed  CAS  Google Scholar 

  9. McMahon GT, Dluhy RG: Glucocorticoid-remediable aldosteronism. Arq Bras Endocrinol Metabol 2004, 48:682–686

    PubMed  Google Scholar 

This paper provides a comprehensive review of glucocorticoid-remediable aldosteronism.

  1. Litchfield WR, New MI, Coolidge C, et al.: Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997, 82:3570–3573

    Article  PubMed  CAS  Google Scholar 

  2. Mosso L, Gomez-Sanchez CE, Foecking MF, et al. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives. Hypertension 2001, 38:688–691

    PubMed  CAS  Google Scholar 

  3. Minowada S, Fujimura T, Takahashi N, et al. Computed tomography-guided percutaneous acetic acid injection therapy for functioning adrenocortical adenoma. J Clin Endocrinol Metab 2003, 88:5814–5817

    Article  PubMed  CAS  Google Scholar 

  4. Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003, 97:554–560

    Article  PubMed  Google Scholar 

  5. Mayo-Smith WW, Dupuy DE: Adrenal neoplasms: CT-guided radiofrequency ablation—preliminary results. Radiology 2004, 231:225–230

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Weill Cornell Medical College, New York, NY, USA

    Tracy-Ann Moo & Rasa Zarnegar

  2. Department of Surgery, San Francisco Medical Center, University of California , San Francisco, CA, USA

    Quan-Yang Duh MD

  3. Surgical Service, Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA, 94121, USA

    Quan-Yang Duh MD

Authors
  1. Tracy-Ann Moo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rasa Zarnegar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Quan-Yang Duh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Quan-Yang Duh MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moo, TA., Zarnegar, R. & Duh, QY. Prediction of Successful Outcome in Patients with Primary Aldosteronism. Curr. Treat. Options in Oncol. 8, 314–321 (2007). https://doi.org/10.1007/s11864-007-0039-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-007-0039-8

Keywords

Search

Navigation